Technology evaluation: huN901-DM1, ImmunoGen.
ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer.
Smith
Suzanne V
SV
Australian Nuclear Science and Technology Organisation (ANSTO), Institute of Materials Engineering and Science, Menai, NSW 2234, Australia. svs@ansto.gov.au
D000080044:Ado-Trastuzumab Emtansine; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019002:CD56 Antigen; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008453:Maytansine / Q000031:analogs & derivatives; D011355:Prodrugs / Q000627:therapeutic use*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019002:CD56 Antigen; D011355:Prodrugs; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine